| Item Type | Name |
|
Concept
|
Vidarabine
|
|
Academic Article
|
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.
|
|
Academic Article
|
Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
|
|
Academic Article
|
Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine.
|
|
Academic Article
|
T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
|
|
Academic Article
|
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
|
|
Academic Article
|
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.
|
|
Academic Article
|
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
|
|
Academic Article
|
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.
|
|
Academic Article
|
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
|
|
Academic Article
|
Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
|
|
Academic Article
|
Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.
|
|
Academic Article
|
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
|
|
Academic Article
|
Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
|
|
Academic Article
|
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
|
|
Academic Article
|
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
|
|
Academic Article
|
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.
|
|
Academic Article
|
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
|
|
Academic Article
|
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
|
|
Academic Article
|
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
|
|
Academic Article
|
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
|
|
Academic Article
|
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
|
|
Academic Article
|
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
|
|
Academic Article
|
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
|
|
Academic Article
|
Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.
|
|
Academic Article
|
Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.
|
|
Academic Article
|
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab).
|
|
Academic Article
|
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.
|
|
Academic Article
|
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
|
|
Academic Article
|
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
|
|
Academic Article
|
Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
|
|
Academic Article
|
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
|
|
Academic Article
|
?2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
|
|
Academic Article
|
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
|
|
Academic Article
|
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
|
|
Academic Article
|
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
|
|
Academic Article
|
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.
|
|
Academic Article
|
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
|
|
Academic Article
|
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
|
|
Academic Article
|
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
|
|
Academic Article
|
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
|